Hearing the Signals: How AI and Real-Time Supply Chain Intelligence Can Keep Pharma Ahead of Disruption

As global supply chains grow increasingly complex, pharmaceutical executives face a new and urgent challenge: the risk of being outpaced by competitors who are listening to market signals faster, adapting more nimbly, and leveraging AI-driven ecosystems to predict disruption before it arrives.^1,2

In this Q&A, Joe Hudicka, entrepreneur, supply chain strategist, and author, discusses the warning signs of a "silent shift" in pharma supply chains, the practical steps leaders can take to build trust in AI tools, and why the concept of "forestreaming" may determine which companies lead the industry and which are left behind.³

Access all four parts of our four-part video interview series with Hudicka:

-The Silent Shift in Pharma Supply Chains

-Building Trust in AI Supply Chains

-Human Oversight Remains Essential, as AI Expands in Pharma Manufacturing and Distribution

-How AI Ecosystems Could Transform Pharma Demand and Crisis Response

PC: You’ve described the concept of a “silent shift” in global supply chains. What signs should pharma executives be watching for that indicate such a shift is underway, and how can they prepare before it becomes disruptive?

Hudicka: This world of global supply—it's complicated, and the easy step for companies to take is to stay siloed, because that's the way we've always done it. That's what our strategies say. When you ask that first question of what sign should anybody look for in any industry, pharma is this one. Framing it that way—it's getting out-competed. If you start seeing longer lead times on supply sourcing, if you start seeing that your supply experience, particular vendors, all of a sudden, is degrading around you, used to be consistent, used to be great, now suddenly, it's fallen off - and you start looking at your transportation relationships and they're canceling pickups, prices are, surging, what's going on around there?

What's going on is competitors are figuring out how to hear signals faster than you, and if they're hearing them faster, they're adapting faster, and so they're getting there ahead of you, and you're just going along the normal way, because it's the way we've always done it. Like I do this RFP process for four months out of the year, and then we sign it, and everything's just going to work magically through the whole year, until little things like pandemics and etc. happen.

When we go status quo, when we stay isolated, we just can't hear what we need to hear. We can't see what we need to see. Somebody else will, I absolutely guarantee it, somebody else will, and they'll get first-mover advantage.

So, the signals you've got to listen to are not going to be the ones inside our own bubble, it's the ones that are happening on the other side of our customers and partners. Are they finding alternatives to do business, and are they doing better over there that they're doing with us?

What practical steps can supply chain leaders take to build trust in AI-driven ecosystems without compromising security or competitive advantage?

We live in global supply chains, and so while the perception over in Europe looking over here, is, wow, America is doing all these things, the reality is, no, most companies are not, which is to the point of the question you raised. Here’s the thing. I have a champion customer with the new product that I've launched around strengthening digital communications for companies. His prior life was Bayer, so pharmaceutical for many, many years.

Here's the approach that he took, he focused on this in his current company by the way, not Bayer - what he did was he focused on machine-generated data first. Look at IoT, look at the internet of things. We've got sensors all over the place in our companies, and they generated piles and piles of data, and we're probably in healthcare regulated to keep the data. What do we do with it? Does it just sit somewhere?

I say the first step is apply AI to the machine-generated data and machine-learning opportunities. If we do that, we can start thinking about things like finding the patterns in the data that can help us predict better equipment maintenance schedules and get proactive instead of reactive. And the thing about that is, not only are we improving our cost and our production, it's easier to get people buying in to trying AI when it's on data, where that data is not dependent on human interaction. It's a machine that generated it. It's the machine that's going to break. It's people that aren't going to get the profit they would have otherwise. It's a lot easier to get people to understand and go for that, and now you've got examples to build trust off of.

In the context of pharmaceutical distribution and manufacturing, where do you see the most critical points where human oversight must remain central?

First and foremost, we've got a concept in pharma technology of IV&V, independent verification and validation. We've got to do our IQs and OQs, and we've got to document, and so that would have to happen whether AI was involved or not. The thing is, we might need to spend a little bit more time showcasing and communicating, making that a little bit more transparent to the larger audience in the company. Where normally that's just an IT thing—IT tells PMO that the box is checked and it passed, or the box is not checked, it failed—here, maybe there needs to be a little bit more celebration, a little bit more communication about looking at how much more data we're processing into information, which is now informing decision points. That acceleration is happening by AI.

AI is assisting us, but the decision point is the human. That's the person, and so it's an assistant and nothing more. That's fundamentally where big tech is—again, through marketing—taking everybody off the rails. What happens in big tech generally is we have to pick, we have to pick a lane, so I'm Microsoft, you're Apple, I'm Teams, you're Slack. It's always about those silos, and the problem in business is ecosystem.

Looking ahead, how do you see AI ecosystems improving the ability of pharma companies to forecast demand, manage shortages, and respond to crises like pandemics or geopolitical disruptions?

So one of the key concepts that I emphasize in the book, I call it “forestreaming,” as opposed to forecasting. Think about forecasting in a fishing analogy of taking one line, throw it in the water, hope we're going to catch dinner, as opposed to being able to drain the lake, walk in, get the one we want, and fill it back up. Forecasting versus forestreaming.

In a forestreaming world, where we're sharing signals as real-time as possible in shifting supply and demand with our customers and partners, geopolitical events that are taking place, we share these signals as they're happening as close as possible, and we hear a more perfect understanding of tomorrow than we ever could in a forecasting world. If we hear it sooner or we adapt faster, and when we adapt faster than somebody else, big fish eat little fish. That's just the way it works.

The thing is, a little fish could become a big fish in a hurry. It could be a smaller company that embraces the idea of the AI ecosystem and makes it easier for their customers and partners to be more resilient—mentally and physically—and, as a result, it could be a dark horse that comes out of nowhere and takes the lead in certain industry segments. I think it's not a matter of how close we are—I think we're there. I think companies don't realize it, and change is inherently hard period.

References

1. 1. FDA Launches PreCheck Pilot Program to Strengthen Domestic Pharmaceutical Manufacturing. US Food & Drug Administration. February 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-precheck-pilot-program-strengthen-domestic-pharmaceutical-manufacturing
2. Haigney S. Copay Accumulators and Programs that Harm Access to Healthcare. Pharmaceutical Technology. February 2, 2026. https://www.pharmtech.com/view/fda-launches-precheck-pilot-program-to-bolster-domestic-drug-manufacturing
3. Barberini L. Relationship Management and the AI Inclusion: The Human Factor. October 1, 2025. LogiPharma USA 2025. Boston.